Acute Exacerbation of Pre-existing Cancer-Related Pain: An Atypical Presentation of an Amivantamab-Induced Infusion-Related Reaction
Abstract
Cancer-related pain affects more than 70% of patients with advanced cancer and it is mediated by tumor invasion and inflammatory cytokine-induced neural sensitization. Anticancer therapies may transiently exacerbate pain through treatment-related inflammatory responses. Amivantamab, an EGFR-MET bispecific antibody approved for EGFR-mutated non-small cell lung cancer, commonly causes infusion-related reactions (IRRs), typically with flushing or respiratory symptoms. We report a case of a 70-year-old woman with EGFR-mutated lung adenocarcinoma who developed a reproducible, transient exacerbation of pre-existing cancer-related pain during initial amivantamab infusions without any systemic abnormalities or clear evidence of radiologic progression. This suggests that acute pain flare is an atypical manifestation of amivantamab-induced IRR.
Related
- Exacerbation of Pre-existing Hypothyroidism Following Enarodustat Administration in a Patient on Peritoneal Dialysis: A Case Report
- An Atypical Abdominal Presentation of Pancreatic Panniculitis in a Patient With Suspected Pancreatic Cancer: A Case Report
- A rare case report: atypical presentation of Klinefelter syndrome in a 24-year-old male at suburban tertiary care hospital in Nepal
- An Atypical Presentation of Richter's Transformation in Chronic Lymphocytic Leukemia: Stroke-Like Onset With Multiorgan Involvement Including the Heart and Seminal Vesicles
- Atypical Presentation of Microscopic Polyangiitis with Pericarditis Manifesting as Right-Sided Heart Failure
BibTeX
@article{yamaguchi2026acute,
title = {{Acute Exacerbation of Pre-existing Cancer-Related Pain: An Atypical Presentation of an Amivantamab-Induced Infusion-Related Reaction}},
author = {Ryutaro Yamaguchi and Yosuke Tamura and Yuki Asai and Kazuhiro Takezaki and Akira Yura and Hideaki Kawaguchi and Yasuyuki Shimazu and Masahiro Arai and Sho Mitsuya and Tomoya Funamoto and Hiroyuki Tsuji and Ninso Matsunaga and Kenjiro Tsuruoka and Takahiko Nakamura and Soichiro Ikeda and Yasuhito Fujisaka},
journal = {Internal Medicine},
year = {2026},
month = jul,
doi = {10.2169/internalmedicine.7268-26},
url = {https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_7268-26/_article},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Acute Exacerbation of Pre-existing Cancer-Related Pain: An Atypical Presentation of an Amivantamab-Induced Infusion-Related Reaction
AU - Ryutaro Yamaguchi
AU - Yosuke Tamura
AU - Yuki Asai
AU - Kazuhiro Takezaki
AU - Akira Yura
AU - Hideaki Kawaguchi
AU - Yasuyuki Shimazu
AU - Masahiro Arai
AU - Sho Mitsuya
AU - Tomoya Funamoto
AU - Hiroyuki Tsuji
AU - Ninso Matsunaga
AU - Kenjiro Tsuruoka
AU - Takahiko Nakamura
AU - Soichiro Ikeda
AU - Yasuhito Fujisaka
PY - 2026
DA - 2026/07/04
JO - Internal Medicine
DO - 10.2169/internalmedicine.7268-26
UR - https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_7268-26/_article
AB - Cancer-related pain affects more than 70% of patients with advanced cancer and it is mediated by tumor invasion and inflammatory cytokine-induced neural sensitization. Anticancer therapies may transiently exacerbate pain through treatment-related inflammatory responses. Amivantamab, an EGFR-MET bispecific antibody approved for EGFR-mutated non-small cell lung cancer, commonly causes infusion-related reactions (IRRs), typically with flushing or respiratory symptoms. We report a case of a 70-year-old woman with EGFR-mutated lung adenocarcinoma who developed a reproducible, transient exacerbation of pre-existing cancer-related pain during initial amivantamab infusions without any systemic abnormalities or clear evidence of radiologic progression. This suggests that acute pain flare is an atypical manifestation of amivantamab-induced IRR.
SN - 1349-7235
SN - 0918-2918
ER -